# Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL

> **NCT05598593** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 70 (estimated)

## Conditions studied

- Cytarabine+Thiotepa + Fludarabine + Busulfan
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

## Interventions

- **DRUG:** cytarabine+thiotepa+ fludarabine + busulfan

## Key facts

- **NCT ID:** NCT05598593
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-23
- **Primary completion:** 2024-09
- **Final completion:** 2025-09
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598593, "Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05598593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*